AASLD 2024
AASLD 2024

Acute Hepatic Porphyria (AHP)

American Association for the Study of Liver Diseases (AASLD) 2024

Congress Details

calanderNovember 15-19, 2024

locationSan Diego, CA, USA

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Oral

Congress Materials

AASLD 2024
icon Presentation Type
Poster
location icon Location
San Diego, CA, USA
icon Title
Impact of givosiran treatment on symptoms between acute attacks of acute hepatic porphyria as assessed by dimension-level analysis of EQ-5D data from the ENVISION study
AASLD 2024
icon Presentation Type
Poster
location icon Location
San Diego, CA, USA
icon Title
Dimension analysis of EQ-5D in patients with acute hepatic porphyria categorized by annualized attack rate to assess any relationship with symptoms occurring between attack

Related Materials

Acute Hepatic Porphyria (AHP)

Clinical features of acute attacks, chronic symptoms, and long-term complications among patients with acute hepatic porphyria in Japan: a real-world claims database study

Orphanet Journal of Rare Diseases

Author(s)

Yutaka Horie, Yuka Yasuoka & Tomohide Adachi

December 2023

Acute Hepatic Porphyria (AHP)

Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial

Journal of Hepatology

Author(s)

David J Kuter, Herbert L Bonkovsky, Susana Monroy, et al

July 2023

Acute Hepatic Porphyria (AHP)

Pharmacokinetic-Pharmacodynamic Model of Urinary δ-Aminolevulinic Acid Reduction After Givosiran Treatment in Patients with Acute Hepatic Porphyria

CPT: Pharmacometrics & Systems Pharmacology

Author(s)

Jongtae Lee, Megan Melch, Gabriel J Robbie

March 2023

Acute Hepatic Porphyria (AHP)

Population Pharmacokinetic Analysis of the RNAi Therapeutic Givosiran in Patients with Acute Hepatic Porphyria

Clinical Pharmacokinetics

Author(s)

Megan Melch, Jongtae Lee, Claudia Jomphe, et al

January 2023

Acute Hepatic Porphyria (AHP)

Quantifying the Impact of Acute Hepatic Porphyria on Well-Being via Patient-Reported Outcomes: Results from the Porphyria Worldwide Patient Experience Research (POWER) Study

JIMD Reports

Author(s)

Amy Dickey, Kristen Wheeden, Desiree Lyon, et al

October 2022

Acute Hepatic Porphyria (AHP)

EXPLORE B: A prospective, long-term natural history study of patients with acute hepatic porphyria with chronic symptoms

Journal of Inherited Metabolic Disease

Author(s)

David Cassiman, Raili Kauppinen, Susana Monroy

September 2022